329 related articles for article (PubMed ID: 26331698)
1. A clinically attainable dose of L-asparaginase targets glutamine addiction in lymphoid cell lines.
Sugimoto K; Suzuki HI; Fujimura T; Ono A; Kaga N; Isobe Y; Sasaki M; Taka H; Miyazono K; Komatsu N
Cancer Sci; 2015 Nov; 106(11):1534-43. PubMed ID: 26331698
[TBL] [Abstract][Full Text] [Related]
2. Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.
Chan WK; Horvath TD; Tan L; Link T; Harutyunyan KG; Pontikos MA; Anishkin A; Du D; Martin LA; Yin E; Rempe SB; Sukharev S; Konopleva M; Weinstein JN; Lorenzi PL
Mol Cancer Ther; 2019 Sep; 18(9):1587-1592. PubMed ID: 31209181
[TBL] [Abstract][Full Text] [Related]
3. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
Panosyan EH; Grigoryan RS; Avramis IA; Seibel NL; Gaynon PS; Siegel SE; Fingert HJ; Avramis VI
Anticancer Res; 2004; 24(2C):1121-5. PubMed ID: 15154634
[TBL] [Abstract][Full Text] [Related]
4. Expanding targets for a metabolic therapy of cancer: L-asparaginase.
Covini D; Tardito S; Bussolati O; Chiarelli LR; Pasquetto MV; Digilio R; Valentini G; Scotti C
Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):4-13. PubMed ID: 21854356
[TBL] [Abstract][Full Text] [Related]
5. Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.
Chien WW; Le Beux C; Rachinel N; Julien M; Lacroix CE; Allas S; Sahakian P; Cornut-Thibaut A; Lionnard L; Kucharczak J; Aouacheria A; Abribat T; Salles G
Sci Rep; 2015 Jan; 5():8068. PubMed ID: 25626693
[TBL] [Abstract][Full Text] [Related]
6. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961).
Grigoryan RS; Panosyan EH; Seibel NL; Gaynon PS; Avramis IA; Avramis VI
In Vivo; 2004; 18(2):107-12. PubMed ID: 15113036
[TBL] [Abstract][Full Text] [Related]
7. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
[TBL] [Abstract][Full Text] [Related]
8. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.
Avramis VI; Tiwari PN
Int J Nanomedicine; 2006; 1(3):241-54. PubMed ID: 17717965
[TBL] [Abstract][Full Text] [Related]
9. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
10. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
[TBL] [Abstract][Full Text] [Related]
11. L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of β-catenin-mutated human hepatocellular carcinoma cells.
Tardito S; Chiu M; Uggeri J; Zerbini A; Da Ros F; Dall'Asta V; Missale G; Bussolati O
Curr Cancer Drug Targets; 2011 Oct; 11(8):929-43. PubMed ID: 21834755
[TBL] [Abstract][Full Text] [Related]
12. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells.
Aslanian AM; Kilberg MS
Biochem J; 2001 Aug; 358(Pt 1):59-67. PubMed ID: 11485552
[TBL] [Abstract][Full Text] [Related]
13. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
14. Microchip CE-LIF method for the hydrolysis of L-glutamine by using L-asparaginase enzyme reactor based on gold nanoparticle.
Qiao J; Qi L; Yan H; Li Y; Mu X
Electrophoresis; 2013 Feb; 34(3):409-16. PubMed ID: 23161488
[TBL] [Abstract][Full Text] [Related]
15. Towards development of biobetter: L-asparaginase a case study.
Tripathy RK; Anakha J; Pande AH
Biochim Biophys Acta Gen Subj; 2024 Jan; 1868(1):130499. PubMed ID: 37914146
[TBL] [Abstract][Full Text] [Related]
16. Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
Wenner KA; Vieira Pinheiro JP; Escherich G; Wessalowski R; Jorch N; Wolff J; Stehn M; Kohlschütter A; Boos J; Janka-Schaub GE
Klin Padiatr; 2005; 217(6):321-6. PubMed ID: 16307417
[TBL] [Abstract][Full Text] [Related]
17. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
[TBL] [Abstract][Full Text] [Related]
18. Rational engineering and insight for a L-glutaminase activity reduced type II L-asparaginase from Bacillus licheniformis and its antileukemic activity in vitro.
Zhou Y; Shen J; Chi H; Zhu X; Lu Z; Lu F; Zhu P
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128690. PubMed ID: 38092107
[TBL] [Abstract][Full Text] [Related]
19. Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies.
Ardalan N; Mirzaie S; Sepahi AA; Khavari-Nejad RA
Med Hypotheses; 2018 Mar; 112():7-17. PubMed ID: 29447943
[TBL] [Abstract][Full Text] [Related]
20. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
Li YT; Kwon YM; Spangrude GJ; Liang JF; Chung HS; Park YJ; Yang VC
J Biomed Mater Res A; 2009 Oct; 91(1):209-20. PubMed ID: 18814276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
